Retrospective Study Assessing the Effect of Avapritinib Versus Best

Updated 05/17/2024

Status Completed

Clinical Trial Summary

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Systemic Mastocytosis
Aggressive Systemic Mastocytosis
Hematologic Neoplasms
Leukemia, Mast-Cell
Mast Cell Leukemia
Mastocytosis
Systemic Mastocytosis With an Associated Hematological Neoplasm

Clinical Trial Details

NCT number	NCT04695431
Study type	Observational
Source	Blueprint Medicines Corporation
Contact
Status	Completed
Phase
Start date	December 2, 2020
Completion date	October 4, 2021

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01807598` - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	Phase 2
	Terminated	`NCT00387426` - Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Phase 2
	Completed	`NCT00898079` - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
	Active, not recruiting	`NCT03580655` - (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis	Phase 2
	Completed	`NCT00112593` - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	N/A
	Completed	`NCT00006251` - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Phase 1/Phase 2
	Terminated	`NCT02415608` - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	Phase 2
	Active, not recruiting	`NCT00118352` - Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Phase 2
	Completed	`NCT02561988` - (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies	Phase 1
	Completed	`NCT01869777` - Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia	N/A
	Completed	`NCT01231919` - MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	Phase 1
	Completed	`NCT01273766` - Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Phase 2
	Terminated	`NCT03214666` - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies	Phase 1/Phase 2
	Completed	`NCT01199562` - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
	Completed	`NCT00014235` - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	N/A
	Completed	`NCT00890747` - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Phase 1
	Completed	`NCT01053494` - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	N/A
	Available	`NCT05219266` - Managed Access Programs for PKC412, Midostaurin